Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call
May 13 2009 - 9:38AM
PR Newswire (US)
WEIFANG, Shandong, China, May 13 /PRNewswire-Asia-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI)
("Shengtai" or "the Company"), a leading manufacturer and
distributor of high-quality, pharmaceutical grade glucose products
in China, today announced that it will issue financial results for
the three months ended March 31, 2009 after the close of the stock
market on Thursday, May 14, 2009. Management will conduct a
conference call on Friday, May 15, 2009 at 8:30 A.M. Eastern
Daylight Time to discuss these results. A question and answer
session will follow management's presentation. Ms. Yiru Melody Shi
(Chief Financial Officer), and Ms. Michelle Wang (Investor
Relations Manager) will be the primary speakers on the call. A live
webcast of the conference call will be available on the Investor
Relations page of Shengtai Pharmaceutical's web site at
http://www.shengtaipharmaceutical.com/ . Please visit the Web site
at least 15 minutes early to register for the webcast and download
any necessary audio software. To participate, please call the
following numbers ten minutes before the call start time: Phone
Number + 1 (877) 407-9205 (North America) Phone Number + 1 (201)
689-8054 (International) A replay of the call will be available
through Thursday, May 21, 2009, at 11:59 P.M. Eastern Daylight
Time. For the replay, please call: Phone Number +1 (877) 660-6853
(North America) Phone Number +1 (201) 612-7415 (International)
Account Number: 286 Conference ID Number: 323305 About Shengtai
Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc. through its
wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the
Chinese operating company of Weifang Shengtai Pharmaceutical Co.,
Ltd., is a leading manufacturer and supplier of pharmaceutical
grade glucose used for medical purposes. It also manufactures and
supplies glucose and cornstarch products to the food, beverage and
industrial production industries in China. Forward-looking
Statements Certain statements made in this news release, may
contain forward-looking statements concerning the Company's
business and products. These statements include, without
limitation, statements regarding our ability to prepare the Company
for growth, future increases in market demand, possible increases
in our market share and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs, but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase our products' applications, cost of raw
materials, downturns in the Chinese and world economy, and other
information detailed from time to time in the Company's filings and
future filings with the United States Securities and Exchange
Commission. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements herein and are
cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by this
cautionary statement. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations. For more information, please contact: Shengtai
Pharmaceutical, Inc. Ms. Yiru Melody Shi Chief Financial Officer
Email: Grayling Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Shengtai Pharmaceutical, Inc. - Ms. Yiru Melody Shi, Chief
Financial Officer, ; Grayling - Eddie Cheung, Investor Relations,
+1-646-284-9414, or Web Site:
http://www.shengtaipharmaceutical.com/
Copyright